会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • METHODS FOR REDUCING ANESTHETIC-INDUCIBLE EPILEPTOGENIC AND NEUROTOXIC EFFECTS
    • 降低麻醉诱导性肾上腺皮质激素和神经毒性作用的方法
    • WO2011146806A1
    • 2011-11-24
    • PCT/US2011/037289
    • 2011-05-20
    • UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.MARTYNYUK, Anatoly, EugenySEUBERT, Christoph, NikolausGRAVENSTEIN, Nikolaus
    • MARTYNYUK, Anatoly, EugenySEUBERT, Christoph, NikolausGRAVENSTEIN, Nikolaus
    • A01N45/00A61K31/56
    • A61K31/585A61K31/08A61K38/11A61K45/06A61K2300/00
    • The disclosure encompasses methods of reducing a neural activity in an animal or human subject. The neural activity may be a seizure that may be, but is not necessarily, an inducible side-effect of an anesthetic in an animal or human subject. The methods include administering to an animal or human subject an anesthetic together with a therapeutic agent selected from an inhibitor of the Na + -K + -2Cl - symport ion co-transporter 1 (NKCC1)agent, a mineralcorticoid receptor (MR) antagonist, or an agonist of an oxytocin receptor or a derivative thereof. The therapeutic agent can be be administered before or with an anesthetic, thereby reducing the likelihood of the onset of a non-anesthesizing effect of the anesthetic or the severity thereof. A suitable mineralcorticoid receptor (MR) antagonist can be 17-spironolactone, and the oxytocin receptor agonist can be, but not limited to, oxytocin, carbetocin, and the like. The neural activity reduced by the methods of the disclosure can include the onset or level of a seizure, a neurotoxicity, a behavioral effect, a cognitive effect.
    • 本公开内容包括减少动物或人类受试者的神经活性的方法。 神经活动可以是可能但并不一定是麻醉剂在动物或人类受试者中的诱导性副作用的发作。 所述方法包括向动物或人类受试者施用麻醉剂,其与选自Na + -K + -2Cl-对称离子共转运蛋白1(NKCC1)抑制剂,盐皮质激素受体(MR)拮抗剂或 催产素受体或其衍生物的激动剂。 治疗剂可以在麻醉之前或与麻醉剂一起施用,从而降低麻醉剂非麻醉作用发生的可能性或其严重性。 合适的皮质激素受体(MR)拮抗剂可以是17-安体舒通内酯,催产素受体激动剂可以是但不限于催产素,卡贝缩酮等。 通过本公开的方法减少的神经活动可以包括发作的发作或水平,神经毒性,行为效应,认知效应。